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Background: Preoperative depressive symptoms are associated with poor outcomes in patients with an
astrocytoma. Cytokines are associated with depressive symptoms in the general population and are important
mediators of tumor growth and progression.
The aims of this study were to: (1) characterize depressive symptoms, other treatment-related symptoms and biological
mediators; and (2) determine whether preoperative depressive symptoms were associated with the selected biological
mediators.
Methods: A prospective, exploratory study was carried out among 22 patients with a high-grade astrocytoma.
Self-report questionnaires and peripheral blood samples were collected on the day of surgery. Tumor tissue was
collected intraoperatively. Self-report questionnaires were assessed at 3, 6, 9, and 12-months postoperatively.
Results: In circulation, serum IL-8 was inversely correlated with depressive symptoms while IL-17 measured in
tumor tissue supernatant was inversely correlated with depressive symptoms. Depressive symptoms showed a
significant increase at 12 months from baseline levels and were positively associated with treatment-related
symptoms at 3 months and symptom distress at 12 months post-surgery.
Conclusions: In this pilot study, depressive symptoms were negatively associated with IL-8 in serum and IL-17
in tumor tissue. The changes among depressive symptoms, treatment-related symptoms and symptom distress highlight
the need for multi-faceted symptom management strategies over the treatment trajectory in this patient population.Background
It is estimated that 24,620 people will be diagnosed with
a primary malignant brain or central nervous system
tumor this year in the United States [1]. Atrocytomas
are the most common primary malignant brain tumor
(PMBT) in adults [2]. Although advances in surgery,
radiation, and chemotherapy have improved length of
survival in patients with an astrocytoma [3], mortality
remains high which underscores the need to better
understand how other factors affect the disease trajec-
tory. Depressive symptoms are a strong prognostic indi-
cator of poor outcome in patients with an astrocytoma* Correspondence: astarkweathe@vcu.edu
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article, unless otherwise stated.[4,5] and several studies have reported an association
with reduced quality of life and survival time regardless
of treatment type or degree of tumor resection [6-9].
While these findings suggest that there may be common
biological mechanisms underlying the influence of de-
pressive symptoms on tumor progression and resistance
to treatment, particularly for an astrocytoma [10-12],
there have been no studies that have simultaneously
examined these factors. Therefore, the aim of this pro-
spective, exploratory study was to characterize depressive
symptoms, other treatment-related symptoms and bio-
logical mediators that are known to influence astrocytoma
growth and progression. A secondary aim was to deter-
mine whether preoperative depressive symptoms were
associated with the selected biological mediators.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Inflammation has long been regarded as a physiological
mechanism associated with depressive symptoms. Evi-
dence in support of this relationship has been demon-
strated by studies that have observed depressive behavior
following administration of proinflammatory cytokines
[particularly interleukin (IL)-1, IL-6, and tumor necrosis
factor-alpha (TNF-α)], either centrally (in the brain) or
peripherally in animals and humans [13-15]. More speci-
fically, IL-1, IL-6, and TNF-α have been shown to play a
role in the etiology of depression by reducing the synthesis
of serotonin in the brain, stimulating hypothalamic and
preoptic noradrenergic neurotransmission, and inhibiting
glucocorticoid receptor functioning thereby leading to
hypothalamic-pituitary-adrenocortical (HPA) axis dy-
regulation [16].
In the central nervous system, astrocytes are the major
glial cell population and act as immunocompetent cells;
that is, they orchestrate local immune responses [17,18].
Part of the lethality associated with astrocytomas, as well
as other gliomas, is due to the influence of an immuno-
suppressive tumor microenvironment which allows the
tumor cells to evade immune surveillance. Cytokines play
a major role in this process, along with other proteins in-
cluding vascular endothelial growth factor (VEGF), matrix
metallopreoteinases (MMPs) and glial fibrillary acidic pro-
tein (GFAP) [19,20] that promote angiogenesis and tumor
growth [21,22]. In the tumor microenvironment, cytokines
may support tumor growth, inhibit it, or play a dual func-
tion [23]. Those which have been found to suppress tumor
growth include IL-2, IL-12, IL-13 and IFN (gamma, beta
and alpha) while IL-4, IL-6, IL-8 and IL-10 predominantly
contribute to tumor growth [24]. Thus, cytokines have
been implicated in contributing to the invasiveness and
vascularization of tumor cells and immunosuppression
within the tumor microenvironment as well as the initi-
ation and persistence of depressive symptoms [25,26].
To date, no studies have simultaneously characterized
depressive symptoms and the local and systemic levels
of these biological mediators in patients with an astrocy-
toma. Noting the high reported rate of depressive symp-
toms in patients with an astrocytoma, the detrimental
effects on quality of life, and compelling data that suggestsTable 1 Symptom scores over time
Pre-surgery
(N = 22)
3 m post-surgery
(N = 21)
6
BDI-II 11.68 ± 1.70 16.66 ± 2.37
MDASI Core 2.11 ± 0.33 3.03 ± 0.27
MDASI BT 1.25 ± 0.25 1.68 ± 0.28
MDASI Interference 3.14 ± 0.55 4.52 ± 0.37
Values given are mean ± standard errors. Abbreviations: m Months, BDI-II Beck Depr
MDASI BT M.D. Anderson Symptom Inventory-Brain Tumor Module.shared mechanisms underlying depressive symptoms and
tumor progression [27,28], we conducted a descriptive
correlational study in patients with an astrocytoma who
were undergoing tumor resection.
Results
Sample demographics
There were a total of 22 patients with a mean age of
45.7 years (SD ± 18.09) who met inclusion criteria and
were enrolled. Of these, there were 9 women (41%) and
13 men (59%) of whom 30% were diagnosed with a pri-
mary (de novo) grade III astrocytoma and 70% with a
primary (de novo) grade IV astrocytoma. Lifetime history
of depression was positive for 7 participants (30%) with
the remaining participants reporting that they had never
received a diagnosis or treatment for depression.
Depressive symptoms
As seen in Table 1, there was a statistically significant in-
crease in the level of depressive symptoms between base-
line and the 12 month follow up assessment (P < .02). The
mean Beck Depression Inventory version II (BDI-II) score
at the time of surgery was 11.68 (SD, 1.7), indicating
minimal depressive symptoms. The mean BDI-II score
increased to 16.66 (SD, 2.37) at 3 months after tumor
resection, slightly decreased to 15.07 (SD, 1.84) and 14.21
(SD, 1.35) at 6 and 9 months post-tumor resection
respectively, and increased to 18.63 (SD, 1.48) at 12 months
post-tumor resection.
Perceived Stress
Levels of perceived stress increased from baseline to
the follow-up period at 3, 6, 9, and 12-months post-
operatively, however, there were no significant diffe-
rences between the scores over time and no significant
association with depressive symptoms.
Treatment-related symptoms
There was a statistically significant rise in the M.D.
Anderson Symptom Inventory (MDASI) Core symptoms
between baseline and the 3 month follow-up appoint-
ment (P < .003). However, there were no significant changes
in the M.D. Anderson Symptom Inventory Brain TumorTime
m post-surgery
(N = 20)
9 m post-surgery
(N = 19)
12 m post-surgery
(N = 19)
15.07 ± 1.84 14.21 ± 1.35 18.63 ± 1.48
2.20 ± 0.18 2.07 ± 0.12 2.59 ± 0.20
1.25 ± 0.16 1.16 ± 0.17 1.85 ± 0.25
4.04 ± 0.42 4.35 ± 0.37 4.61 ± 0.31
ession Inventory version II, MDASI Core M.D. Anderson Symptom Inventory,
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Figure 2 Additional biological factors in serum and tumor tissue.
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increased significantly between baseline and the 12 month
follow-up assessment (P < .002). Baseline depressive symp-
toms were associated with the MDASI Core symptoms
(P < .01) and interference scores (P < .002).
Biological factors
The biological data from serum and brain tumor super-
natant from tissue acquired at the time of surgery is pre-
sented in Figure 1 and Figure 2. Spearman correlations
were performed to investigate the possibility of a rela-
tionship between biological mediators in the serum and
tumor tissue, as well as between depressive symptoms
and biological mediators. There were no significant asso-
ciations between the serum and brain tumor levels. Of
the serum cytokine levels, IL-8 was significantly nega-
tively correlated with depressive symptoms (Spearman’
ρ = −.70, P < .0004) while IL-17 was the only tumor tissue
cytokine associated with depressive symptoms (Spearman’
ρ = −.50, P < .03).
Discussion
According to the cut-off scores of the Beck Depression
Inventory version II (BDI-II), depressive symptom were
minimal at baseline but showed a statistically significant
increase at 12 months from baseline levels. There was
also a significant rise in treatment-related symptoms at
3 months following tumor resection as well as a signifi-
cant increase in symptom distress (interference score) at
12 months. These results are similar to those reported
by Litofsky et al. [7] in which depressive symptoms in-
creased over the first 6-months following tumor resec-
tion, however, in their study the MF-36 Mental Health
score was used to quantify depressive symptoms and
treatment-related symptoms were not measured. A sys-
tematic review of studies evaluating depression in glioma
patients concluded that depressive symptoms, regardless
of the measure used, tend to increase in frequency and
severity over time after tumor resection [29]. The present
study enhances understanding about depressive symptoms0
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Figure 1 Cytokine levels in serum and brain tumor tissue.by identifying a time-related course in which there is a
simultaneous rise in the severity of treatment-related
symptoms at 3 months after tumor resection as well as an
increase in symptom distress at 12 months.
The association between depressive symptoms and
treatment-related symptoms is not surprising as previous
studies have observed that depressive symptoms tend to
co-occur with treatment-related symptoms, including
cognitive impairment, sleep disturbances and pain in pa-
tients with a brain tumor [29,30]. Previous studies have
also reported an association among depressive symp-
toms and decreased physical functioning, quality of life
and survival in patients with brain cancer [6-9]. Mainio
et al. [31] reported that increased severity of depression
in patients with a brain tumor after tumor resection was
associated with a lower functional status as indicated by
the Karnofsky Performance Scale. Depression defined as
a BDI score of 10 or greater predicted shorter survival in
patients with low-grade glioma [8]. In a retrospective re-
view of 1052 patients with malignant astrocytoma under-
going tumor resection, a preoperative clinical diagnosis of
depression was a predictor of shorter survival [6]. The re-
sults of the present study demonstrate that depressive
symptoms and symptom distress simultaneously increase
at 12 months post-tumor resection. This finding suggests
that depressive symptoms are more likely to occur when
treatment-related symptoms begin to negatively impact
daily functioning.
Many of the peripheral cytokines were elevated at the
time of surgery . Of particular interest were the elevated
levels of IL-6 and TNF-α as sustained elevations of these
cytokines have been associated with “sickness behavior”,
however, the levels of these cytokines were not associ-
ated with depressive symptoms in this sample. In con-
trast, serum levels of IL-8 were inversely associated with
depressive symptoms. Although in the tumor micro-
environment, IL-8 has chemotactic, tumorigenic and
proangiogenic properties and has been shown to induce
infiltration of tumor-associated macrophages (TAMs)
Starkweather et al. BMC Research Notes 2014, 7:423 Page 4 of 7
http://www.biomedcentral.com/1756-0500/7/423[17,32], the present finding suggests a possible deregula-
tion of peripheral neutrophil activation associated with
depressive symptoms.
This study did not find an association between plasma
and tumor levels of the selected cytokines. In contrast, a
study by Samaras et al. [33] found that levels of IL-6 and
IL-10 in astrocytic neoplasms and peripheral blood were
highly correlated and that the principal IL-6 positive cell
type was the neoplastic astrocyte, whereas microglial
cells and macrophages were the major source of IL-10.
One of the most intriguing findings of this pilot study
was the inverse relationship between depressive symp-
toms and brain tumor IL-17 levels. It was recently
reported that IL-17 expression within tumor tissue was
associated with progression-free survival in patients with
an astrocytoma [34]. In that study, the authors con-
cluded that high levels of IL-17 expression in tumor tis-
sues may be a good prognostic marker for patients with
grade IV astrocytoma. IL-17 is a CD4 T cell-derived pro-
inflammatory cytokine that may enhance tumor suppres-
sion by signaling Th17 cells into the brain tissue. Th17
cells have enhanced migratory capabilities into the CNS
because of their ability to penetrate the blood brain bar-
rier [34]. However, due to methodological differences
between studies (ie. measurement of IL-17 expression
vs. level of IL-17 in tumor tissue supernatant) the signifi-
cance of the present finding remains unclear and no
causal inferences can be made based on the design of
the study. Further investigations are necessary to exa-
mine the relationship between IL-17 in tumor tissue and
depressive symptoms in a larger sample of patients and
to examine the influence on patient outcomes.
Limitations
This exploratory study was designed to explore the rela-
tionships among depressive symptoms and the selected
biological factors. Most patients in the study reported
minimal to moderate levels of depressive symptoms.
Since the study did not include a psychological exami-
nation to differentiate participants with major depression
disorder (MDD), the study findings cannot be genera-
lized to patients with MDD. However, it can be argued
that even subsyndromal MDD is associated with signifi-
cant morbidity in individuals with cancer. In this
context, the study findings warrant further investigation.
Conclusions
In this sample of patients with a grade III or IV astro-
cytoma, depressive symptoms varied over the treatment
trajectory with a significant increase at 12 months. De-
pressive symptoms were significantly associated with
treatment-related symptoms at 3 months post-operative
and symptom distress at 12 months postoperative. These
findings suggest that depressive symptoms are morelikely to occur when treatment-related symptoms in-
crease or when they begin to negatively impact daily
functioning. As many aspects of depressive symptoms
overlap with treatment-related symptoms, including cog-
nitive impairment and sleep disturbances, the results
suggest that multi-faceted symptom management stra-
tegies may be beneficial during the postoperative period.
Serum level of IL-8 and tumor tissue level of IL-17 were
negatively associated with depressive symptoms, how-
ever, further research is necessary in order to determine
whether these findings can be replicated in a larger
sample.Methods
This study used a prospective, exploratory, repeated-
measures design to characterize depressive symptoms,
treatment-related symptoms and pro- and anti-inflammatory
cytokines (as well as MMP-2, MMP-9, and GFAP) in tumor
tissue and in blood at the time of tumor resection. Patient
reported symptoms were also assessed at 3, 6, 9, and
12-months postoperatively. The follow-up time points
were selected based on the normal course of patients
after tumor resection, which includes starting chemothe-
rapy and radiation, prognostic evaluations of the tumor
response to treatment, and continued surveillance.Participants and procedures
This study was approved by the Institutional Review
Board (IRB) of Virginia Commonwealth University, a
large urban university health system in the mid-Atlantic
region that served as the study site for recruitment and
data collected processes. The study was conducted in
accordance with the Department of Health and Human
Services’ policy for protection of human research subjects.
Eligible patients were referred and screened by re-
search collaborators in the Department of Neurological
Surgery. Informed consent was obtained from each par-
ticipant. Inclusion criteria included males and females
18 years or older, with clinical diagnosis of a malignant
astrocytoma (Grade III or IV) who were scheduled for
tumor resection. In addition, participants had to be flu-
ent in English and without history of immune-related
disease or previous cancer diagnosis. Patients were ineli-
gible if they were unable to provide informed consent
due to altered cognitive status as evidenced by a Mini-
Mental Status Examination score of 23 or lower (0–23)
or if they were currently taking an anxiolytic or anti-
depressant medication. Subjects who enrolled in the study
but were subsequently started on an anti-depressant du-
ring the postoperative period were not followed and their
data was not used in the analyses. Recruitment and data
collection took place between December 2010 and
December 2012.
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were asked to complete the study questionnaires in a
private room. When a participant was found to be at risk
for severe depression (≥20 on the BDI-II) or verbalized
difficulty dealing with depressive symptoms, their phy-
sician was notified as explained in the informed consent.
Following completion of the questionnaires, a blood spe-
cimen was collected adhering to a standard venipuncture
protocol from an antecubital site on the day of surgery.
Blood specimens were immediately transported on ice to
the laboratory for processing.
As part of standard care for the treatment of an astro-
cytoma, all of the participants underwent a gross total
resection, which has been associated with longer survival
and improved neurological function [35]. Tissue speci-
mens acquired during the surgery were immediately
packed on ice and transported to the laboratory for pro-
cessing. Surgery was followed by involved-field radio-
therapy ranging from a total dose of 54 to 60 Gy and
adjuvant chemotherapy with temozolomide.
Measures
Demographics
Demographic and clinical characteristics of study partici-
pants (e, g., age, gender, race and ethnicity, lifetime his-
tory of depression) were recorded at baseline for each
participant. Lifetime history of depression was quantified
by asking the patient whether they had ever received a
diagnosis or been treated for depression. If the patient
answered affirmatively to either diagnosis or treatment,
a positive lifetime history of depression was recorded.
Age was included as a continuous variable in analyses,
while gender and lifetime history of depression were
dichotomous.
Depressive symptoms
Depressive symptoms were measured using the Beck
Depression Inventory version II (BDI-II). The BDI-II is
a 21-item self-report instrument intended to assess the
existence and severity of symptoms of depression as
listed in the American Psychiatric Association’s Diagnostic
and Statistical Manual of Mental Disorders Fourth Edi-
tion (DSM-IV; 1994) [36]. There is a four-point scale for
each item ranging from 0 to 3. On two items (16 and 18)
there are seven options to indicate either an increase or
decrease of appetite and sleep. Summing the 21 items pro-
vides a total BDI-II score that is used to provide a catego-
rical rating of symptom severity (0 to 13 indicates minimal
symptoms of depression, 14 to 19 mild symptoms, 20 to
28 moderate symptoms, and 29 to 63 severe symptoms).
The total score was used in the analyses to determine the
relationships between depressive symptoms and biological
factors. Validity for the BDI-II has been well established in
patients with a PMBT [29].Perceived Stress
The Perceived Stress Scale (PSS) is the most widely used
psychological instrument for measuring the perception
of stress. PSS is a brief 10-item scale measuring the degree
to which experiences are appraised as uncontrollable [37].
Individuals rate their responses using a 5-point Likert
scale. A total score is provided by adding the responses
together, with a higher score indicating a higher level of
perceived stress. Internal consistency of the PSS ranges
from 0.75-0.86 and test-retest reliability is 0.85 [38].
Treatment-related symptoms
The M.D. Anderson Symptom Inventory-Brain Tumor Mo-
dule (MDASI-BTM) was used to measure treatment-related
symptoms. The MDASI-BTM measures six symptom con-
structs, including affective, cognitive, focal neurological
deficits, treatment-related symptoms, general/disease-
related symptoms, and gastrointestinal symptoms [39].
The MDASI-BTM is a 22-item instrument consisting
of 11-point scales (0–10) for each item. Participants
are asked to indicate the presence and severity of each
symptom in the last 24 hours, with 0 being “not
present” and 10 being “as bad as you can imagine”.
Items of the core symptoms (Core = 13 items) and
brain tumor module symptom items (BT = 9 items) are
summed and divided by the number of items in each
category to provide a mean core symptom score and
mean brain tumor module score. Interference (SD = 6
items) measures how much symptoms have interfered
with different aspects of a patient’s life in the last
24 hours, including interference in general activity,
mood, work, relations with other people, walking, and
enjoyment of life. The mean of the interference items
is used as a measure of overall symptom distress. Total
Core, BT, and Interference scores were used in the
statistical analyses. The six constructs of the MDASI-
BTM have been shown to be sensitive to disease seve-
rity, treatment status, and disease progression [39].
Biological factors
Levels of pro- and anti-inflammatory cytokines, MMP-2,
MMP-9 and GFAP were measured in serum and tumor
specimens taken at the time of surgical resection. Blood
samples were collected via venipuncture using a 10 mL
serum separator vacutainer, immediately placed on ice
and delivered to the laboratory for processing. All speci-
mens were aliquoted immediately, frozen, and stored in
a −80°C freezer until batch processing. Tumor tissue
specimens were collected at the time of biopsy/resection
intraoperatively as part of normal clinical procedures.
No alterations in the surgery were required for this as-
pect of data collection. A 1.5×1.5.×0.5 cm strip of tumor
specimen was cut from the tumor center and placed in a
sterile container as previously described by Samaras
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directly to the laboratory by a research team member.
Under a reverse-flow hood each specimen was cut into
three equal strips and each strip was placed in a cryovial
that was snap frozen in liquid N2 and stored in a −80°C
freezer until batch processing. At the time of analysis,
each specimen was thawed under a reverse-flow hood
and chopped into 1 mm2 pieces using crossed scalpels.
The tissue fragments were immediately placed in a
universal tube containing 1.5 mL of cell lysis buffer
(Bio-Rad; Hercules, CA). The tissue was disrupted by
drawing the samples up and down through a pipette
tip 20 times followed by orbital agitation for 20 minutes
at 300 rpm and 4°C. The samples were then centri-
fuged at 4500 g for 15 minutes at 4°C. Thetissue super-
natant was collected for cytokine analysis using a Bio-Plex®
instrument following the manufacturer’s instructions.
Cytokines, GFAP, MMP-2 and MMP-9 were measured
in serum and tumor supernatant using the Human 17-
plex panel that includes interleukin (IL) 1beta (IL-1ß),
IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-
12p70, IL-13, IL-15, IL-17, VEGF, and TNF-α; and stan-
dardized ELISA kits (Biovendor, Candler, NC). Analysis
was conducted using the Bio-Plex® (Bio-Rad; Hercules,
CA). All samples were run in triplicate and the data was
expressed as the mean ± standard error. The assays
accurately measure cytokine values in the range of
1–2,500 pg/ml, are precise (intra-assay CV <10%, inter-
assay CV <15%), and show less than 1% cross-reactivity
with other molecules.
Statistical analyses
Means and standard deviations of the demographic data
were used to describe the sample. The distributions of
the biological data were graphically inspected and are pre-
sented as the mean ± standard error (SE). Student t-tests
were used to evaluate differences in the patient-reported
symptom scores over time and Pearson correlation coeffi-
cients were used to assess relationships between depres-
sive symptom scores and treatment-related symptoms.
Although there is controversy regarding whether to log-
transform cytokine data to create normal distributions,
this approach may not be ideally suited for identifying
clinically important levels of the biological factors mea-
sured. Thus, Spearman rank correlations were performed
for the nonparametric cytokine data. Due to the variance
in serum cytokine levels, the level of significance was set
at P < .001. All analyses were conducted using SigmaPlot
(Systat Software, Inc., San Jose, CA). A power analysis was
calculated using a study that reported significant diffe-
rences in depressive symptoms among patients with a
brain tumor [6] and suggested a minimum of 20 subjects
were needed to obtain 90% power or greater at P < .05
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